APTX · Aptinyx Inc

-

Please sign in to comment on APTX

1 Comment

Admin

4 years, 1 month ago

Aptinyx Inc is currently in a long term downtrend where the price is trading 15.5% below its 200 day moving average.

From a valuation standpoint, the stock is 92.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 100.6.

Aptinyx Inc's total revenue sank by 100.0% to $0 since the same quarter in the previous year.

Its net income has increased by 16.6% to $-11M since the same quarter in the previous year.

Finally, its free cash flow grew by 49.0% to $-8M since the same quarter in the previous year.

Based on the above factors, Aptinyx Inc gets an overall score of 3/5.

ISIN	US03836N1037
Exchange	NASDAQ
CurrencyCode	USD
Sector	Healthcare
Industry	Biotechnology

PE Ratio	None
Target Price	0.5
Market Cap	7M
Dividend Yield	0.0%
Beta	1.22

ABOUT

Aptinyx Inc

Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.

APTX · Aptinyx Inc

-

Aptinyx Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Aptinyx Inc using a moving average strategy